STRO-004 vs Tisotumab Vedotin Humax-tf-adc
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: Tissue Factor (TF) · full Non-Small Cell Lung Cancer pipeline
STRO-004
Developed by Sutro Biopharma, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07227168 (registry estimate)
No aligned efficacy figure on record for this race.
Tisotumab Vedotin Humax-tf-adc · Tivdak
Marketed by Pfizer and partners
NCT02001623 · Phase 1/2 · completed
This was an open-label, single-arm phase 1/2 safety study: 195 patients with advanced solid tumors all received tisotumab vedotin in dose-escalation cohorts (3–6 patients) and tumor-specific expansion cohorts, with no randomization, blinding, placebo, or active control. The primary endpoints were counts of treatment-emergent adverse events, so the results are descriptive safety/tolerability data only; there was no comparator arm or formal statistical comparison to establish efficacy. Because the design provides no controlled evidence of benefit, the evidence grade is weak.
Reported efficacy
Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events (Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.); Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events (Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.): Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events (Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.): Dose Escalation Part: 0.3 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 1 Participants; CTCAE Grade >=3 TEAEs: 2 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 0.6 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 1 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 3 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 0.9 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 0 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 1 Participants; TEAEs Related to Study Drug: 2 Participants | Dose Escalation Part: 1.2 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 1 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 1.5 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 2 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 1.8 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 3 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 2.0 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 2 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 2.2 mg/kg — TEAEs: 6 Participants; Serious TEAEs: 4 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 4 Participants; TEAEs Related to Study Drug: 6 Participants (not_applicable)
Result source: NCT02001623
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | STRO-004 | Tisotumab Vedotin Humax-tf-adc |
|---|---|---|
| PFS, median | —Not reported | 4.2bNCT0200162320 other results
|
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | 24%bNCT0200162314 other results
|
| Duration of response, median | —Not reported | 4.3bNCT020016233 other results
|
PFS, median
- STRO-004
- —Not reported
- Tisotumab Vedotin Humax-tf-adc
- 4.2bNCT02001623
20 other results
- 2.5 NCT02001623
- 2.3 NCT02001623
- 3 NCT02001623
- 3 NCT02001623
- 3.0 NCT02001623
- 2.6 NCT02001623
- 2.8 NCT02001623
- 4.0 NCT02001623
- 1.4 NCT02001623
- 6.3 NCT02001623
- 1.4 NCT02001623
- 2.6 NCT02552121
- 1.4 NCT02001623
- 1.2 NCT02001623
- 2.5 NCT02552121
- 1.9 NCT02552121
- 3.2 NCT02552121
- 2.8 NCT02552121
- 5.1 NCT02552121
- 1.1 NCT02552121
OS, median
- STRO-004
- —Not reported
- Tisotumab Vedotin Humax-tf-adc
- —Not reported
ORR
- STRO-004
- —Not reported
- Tisotumab Vedotin Humax-tf-adc
- 24%bNCT02001623
14 other results
- 0% NCT02001623
- 27% NCT02001623
- 7% NCT02001623
- 13% NCT02001623
- 13% NCT02001623
- 14% NCT02001623
- 0% NCT02001623
- 0% NCT02001623
- 0% NCT02001623
- 0% NCT02001623
- 33% NCT02001623
- 0% NCT02001623
- 0% NCT02001623
- 0% NCT02001623
Duration of response, median
- STRO-004
- —Not reported
- Tisotumab Vedotin Humax-tf-adc
- 4.3bNCT02001623
3 other results
- 7.4 NCT02001623
- 4.2 NCT02001623
- 4.9 NCT02001623
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
STRO-004: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. STRO-004: 0 of 4 rows · Tisotumab Vedotin Humax-tf-adc: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tisotumab Vedotin Humax-tf-adc |
|---|---|
| Dropout rate | 100%2.2 mg/kga NCT02001623 · Phase 1/2 · monotherapy show 24 more results100%2.0 mg/kg NCT02001623 · Phase 1/2 · monotherapy 100%1.8 mg/kg NCT02001623 · Phase 1/2 · monotherapy 100%1.5 mg/kg NCT02001623 · Phase 1/2 · monotherapy 66.7%1.2 mg/kg NCT02001623 · Phase 1/2 · monotherapy 100%0.9 mg/kg NCT02001623 · Phase 1/2 · monotherapy 100%0.6 mg/kg NCT02001623 · Phase 1/2 · monotherapy 100%0.3 mg/kg NCT02001623 · Phase 1/2 · monotherapy 100%Dose Expansion Part: Bladder Cance NCT02001623 · Phase 1/2 · monotherapy 96.4%Dose Expansion Part: Cervical Canc NCT02001623 · Phase 1/2 · monotherapy 100%Dose Expansion Part: Endometrial C NCT02001623 · Phase 1/2 · monotherapy 100%Dose Expansion Part: Esophageal Ca NCT02001623 · Phase 1/2 · monotherapy 93.3%Dose Expansion Part: Non-Small Cel NCT02001623 · Phase 1/2 · monotherapy —Dose Expansion Part: Non-Small-Cel NCT02001623 · Phase 1/2 · monotherapy 97.2%Dose Expansion Part: Ovarian Cance NCT02001623 · Phase 1/2 · monotherapy 100%Dose Expansion Part: Prostate Canc NCT02001623 · Phase 1/2 · monotherapy n/a: no completion milestone NCT03245736 · Phase 2 · registry result, not featured evidence —3q4wk 1.2 mg/kg NCT02552121 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone3q4wk 0.9 mg/kg NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2 Cohort Expansion: Cohort 3 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2 Cohort Expansion: Cohort 5 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2: Cohort Expansion: Cohort 1 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2: Cohort Expansion: Cohort 2 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2: Cohort Expansion: Cohort 4 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2: Cohort Expansion: Cohort 6 NCT02552121 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 50%2.2 mg/kga NCT02001623 · Phase 1/2 · monotherapy show 24 more results0%2.0 mg/kg NCT02001623 · Phase 1/2 · monotherapy 33.3%1.8 mg/kg NCT02001623 · Phase 1/2 · monotherapy 0%1.5 mg/kg NCT02001623 · Phase 1/2 · monotherapy 0%1.2 mg/kg NCT02001623 · Phase 1/2 · monotherapy 0%0.9 mg/kg NCT02001623 · Phase 1/2 · monotherapy 0%0.6 mg/kg NCT02001623 · Phase 1/2 · monotherapy 0%0.3 mg/kg NCT02001623 · Phase 1/2 · monotherapy 26.7%Dose Expansion Part: Bladder Cance NCT02001623 · Phase 1/2 · monotherapy 10.9%Dose Expansion Part: Cervical Canc NCT02001623 · Phase 1/2 · monotherapy 28.6%Dose Expansion Part: Endometrial C NCT02001623 · Phase 1/2 · monotherapy 0%Dose Expansion Part: Esophageal Ca NCT02001623 · Phase 1/2 · monotherapy 20%Dose Expansion Part: Non-Small Cel NCT02001623 · Phase 1/2 · monotherapy —Dose Expansion Part: Non-Small-Cel NCT02001623 · Phase 1/2 · monotherapy 13.9%Dose Expansion Part: Ovarian Cance NCT02001623 · Phase 1/2 · monotherapy 33.3%Dose Expansion Part: Prostate Canc NCT02001623 · Phase 1/2 · monotherapy 20% NCT03245736 · Phase 2 · registry result, not featured evidence —3q4wk 1.2 mg/kg NCT02552121 · Phase 1/2 · registry result, not featured evidence 33.3%3q4wk 0.9 mg/kg NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2 Cohort Expansion: Cohort 3 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2 Cohort Expansion: Cohort 5 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2: Cohort Expansion: Cohort 1 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2: Cohort Expansion: Cohort 2 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2: Cohort Expansion: Cohort 4 NCT02552121 · Phase 1/2 · registry result, not featured evidence —Part 2: Cohort Expansion: Cohort 6 NCT02552121 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 66.7%2.2 mg/kga NCT02001623 · Phase 1/2 · monotherapy show 24 more results66.7%2.0 mg/kg NCT02001623 · Phase 1/2 · monotherapy 66.7%1.8 mg/kg NCT02001623 · Phase 1/2 · monotherapy 66.7%1.5 mg/kg NCT02001623 · Phase 1/2 · monotherapy 66.7%1.2 mg/kg NCT02001623 · Phase 1/2 · monotherapy 0%0.9 mg/kg NCT02001623 · Phase 1/2 · monotherapy 33.3%0.6 mg/kg NCT02001623 · Phase 1/2 · monotherapy 66.7%0.3 mg/kg NCT02001623 · Phase 1/2 · monotherapy 46.7%Dose Expansion Part: Bladder Cance NCT02001623 · Phase 1/2 · monotherapy 47.3%Dose Expansion Part: Cervical Canc NCT02001623 · Phase 1/2 · monotherapy 35.7%Dose Expansion Part: Endometrial C NCT02001623 · Phase 1/2 · monotherapy 53.3%Dose Expansion Part: Esophageal Ca NCT02001623 · Phase 1/2 · monotherapy —Dose Expansion Part: Non-Small Cel NCT02001623 · Phase 1/2 · monotherapy 40%Dose Expansion Part: Non-Small-Cel NCT02001623 · Phase 1/2 · monotherapy 36.1%Dose Expansion Part: Ovarian Cance NCT02001623 · Phase 1/2 · monotherapy 33.3%Dose Expansion Part: Prostate Canc NCT02001623 · Phase 1/2 · monotherapy — NCT03245736 · Phase 2 · registry result, not featured evidence 33.3%3q4wk 1.2 mg/kg NCT02552121 · Phase 1/2 · registry result, not featured evidence 33.3%3q4wk 0.9 mg/kg NCT02552121 · Phase 1/2 · registry result, not featured evidence 0%Part 2 Cohort Expansion: Cohort 3 NCT02552121 · Phase 1/2 · registry result, not featured evidence 0%Part 2 Cohort Expansion: Cohort 5 NCT02552121 · Phase 1/2 · registry result, not featured evidence 81.8%Part 2: Cohort Expansion: Cohort 1 NCT02552121 · Phase 1/2 · registry result, not featured evidence 66.7%Part 2: Cohort Expansion: Cohort 2 NCT02552121 · Phase 1/2 · registry result, not featured evidence 40%Part 2: Cohort Expansion: Cohort 4 NCT02552121 · Phase 1/2 · registry result, not featured evidence 33.3%Part 2: Cohort Expansion: Cohort 6 NCT02552121 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | 2.2 mg/kga decreased appetite 83.3% alopecia 66.7% epistaxis 66.7% NCT02001623 · Phase 1/2 · monotherapy show 22 more results0.9 mg/kg stomatitis 66.7% alanine aminotransferase increased 33.3% anaemia 33.3% NCT02001623 · Phase 1/2 · monotherapy 3q4wk 1.2 mg/kg conjunctivitis 100% epistaxis 83.3% myalgia 83.3% NCT02552121 · Phase 1/2 · registry result, not featured evidence 3q4wk 0.9 mg/kg epistaxis 100% conjunctivitis 66.7% decreased appetite 66.7% NCT02552121 · Phase 1/2 · registry result, not featured evidence abdominal pain 100% alopecia 100% decreased appetite 100% NCT02552121 · Phase 1/2 · registry result, not featured evidence abdominal discomfort 0% abdominal pain 0% abdominal pain lower 0% NCT02552121 · Phase 1/2 · registry result, not featured evidence epistaxis 63.6% fatigue 54.5% alopecia 45.5% NCT02552121 · Phase 1/2 · registry result, not featured evidence acute kidney injury 33.3% alopecia 33.3% anaemia 33.3% NCT02552121 · Phase 1/2 · registry result, not featured evidence diarrhoea 80% fatigue 80% abdominal pain 60% NCT02552121 · Phase 1/2 · registry result, not featured evidence alopecia 66.7% diarrhoea 66.7% epistaxis 66.7% NCT02552121 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tisotumab Vedotin Humax-tf-adc
show 14 more results
show 59 more results
show 22 more results
show 6 more results
show 8 more results
show 8 more results
show 8 more results
show 8 more results
show 1 more result
show 5 more results
show 7 more results
show 7 more results
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: STRO-004's landscape · Tisotumab Vedotin Humax-tf-adc's landscape